131I-MIBG WITH INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 (摘自ClinicalTrials.gov网站) 放射性药物，如碘I 131间苯基胍，可能会将辐射直接带到肿瘤细胞，而不会损害正常细胞。化疗中使用的药物，如卡铂、依托泊苷和马法兰，以不同的方式阻止肿瘤细胞的生长，要么是通过杀死细胞，要么是通过阻止它们分裂。放射疗法使用高能X射线杀死肿瘤细胞。自体外周干细胞或骨髓移植可能能够取代被化疗和放射治疗摧毁的造血细胞。给予碘I131间苯基胍和联合化疗与自体外周干细胞或骨髓移植，可能会允许进行更多的化疗，从而杀死更多的肿瘤细胞。在自体外周干细胞或骨髓移植后进行放射治疗可能会杀死所有剩余的肿瘤细胞。 这项第二阶段的试验正在研究给予碘I 131间苯基胍结合化疗和放射治疗在治疗复发或难治性神经母细胞瘤接受自体外周干细胞或骨髓移植的患者中的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine, may carry radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such as carboplatin, etoposide, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. An autologous peripheral stem cell or bone marrow transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Giving iodine I 131 metaiodobenzylguanidine and combination chemotherapy with an autologous peripheral stem cell or bone marrow transplant may allow more chemotherapy to be given so that more tumor cells are killed. Giving radiation therapy after an autologous peripheral stem cell or bone marrow transplant may kill any remaining tumor cells. This Phase II trial is studying how well giving iodine I 131 metaiodobenzylguanidine together with combination chemotherapy and radiation therapy works in treating patients who are undergoing an autologous peripheral stem cell or bone marrow transplant for relapsed or refractory neuroblastoma.